第三剂新冠疫苗相关高代谢淋巴结病持续时间短,罕见于肿瘤患者PET-CT解读干扰
本研究纳入179例接受第三剂BNT162b2疫苗后行[18F]FDG PET-CT的肿瘤患者,疫苗与成像中位间隔8天。任何级别疫苗相关高代谢淋巴结病(VAHL)发生率为47.5%,3-4级为8.9%;接种后5天内扫描中82.5%可见VAHL,3-4级占28.1%,但超过5天未检出3-4级VAHL。仅2例无法区分VAHL与恶性淋巴结病。
要点
- 第三剂BNT162b2后5天内PET-CT常见VAHL,但3-4级VAHL在6天及以上扫描中未观察到。
- 接种后5天内扫描中3-4级VAHL占28.1%,高龄和肥胖患者3-4级VAHL可能性更低。
- 仅2/179例无法区分VAHL与恶性淋巴结病,对PET-CT解读干扰少见。
核心结论
- 第三剂BNT162b2疫苗后5天内行[18F]FDG PET-CT常见VAHL,但高级别VAHL在接种6天及以上扫描中不太可能观察到。
研究设计与样本
- 纳入179例连续肿瘤患者,在第三剂BNT162b2疫苗接种后行[18F]FDG PET-CT,评估VAHL存在及特征,疫苗与成像中位间隔8天(IQR 5-14)。
主要发现
- 任何级别VAHL发生率为47.5%,3-4级VAHL发生率为8.9%。
- 接种后5天内扫描中82.5%可见VAHL,3-4级VAHL占28.1%;超过5天扫描未检出3-4级VAHL。
- 仅2/179例无法区分VAHL与恶性淋巴结病。
- 多变量logistic回归显示,3-4级VAHL的独立预测因素为疫苗与成像间隔短(Pv<0.01)、年轻年龄(Pv<0.01)和较低BMI(Pv=0.03)。
临床怎么用
- 肿瘤患者第三剂BNT162b2疫苗接种后5天内行[18F]FDG PET-CT时,应警惕VAHL可能,但高级别VAHL在6天及以上扫描中罕见。
- 高龄和肥胖患者出现3-4级VAHL的可能性更低,解读时可结合接种时间、年龄和BMI综合判断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The incidence of COVID-19 vaccine-associated hypermetabolic lymphadenopathy (VAHL) is high following the administration of the first and second BNT162b2 vaccine doses. The impact of this finding on [18F]FDG PET-CT interpretation and its correlation with the induced humoral immunity have been reported. Assuming the amnestic immune response is different following the third vaccine dose, we aimed to explore the incidence of VAHL over time after the third BNT162b2 dose administration, and its relevance to [18F]FDG PET-CT interpretation in oncologic patients. METHODS: A total of 179 consecutive oncologic patients that underwent [18F]FDG PET-CT after a third BNT162b2 vaccine dose were included. The presence of VAHL was assessed. On VAHL-positive scans, the SUVmax, number, location, and size of the "hot" nodes were recorded. The median time interval between vaccination and imaging was 8 (IQR, 5-14) days. RESULTS: The incidences of all-grade VAHL and grade 3-4 VAHL were 47.5% and 8.9%, respectively. VAHL was identified on 82.5% of studies performed within the first 5 days from vaccination. Grade 3-4 VAHL was observed on 28.1% of studies performed within the first 5 days from vaccination, but was not detected on studies performed more than 5 days from vaccination. Separation between VAHL and malignant lymphadenopathy was not possible in only 2 of the 179 study patients. On a multivariable logistic regression, independent predictors of grade 3-4 VAHL were short time interval between vaccination and imaging (Pv < 0.01), younger age (Pv < 0.01), and lower BMI (Pv = 0.03). CONCLUSION: VAHL is commonly identified on [18F]FDG PET-CT performed within the first 5 days from the third BNT162b2 vaccine dose administration. High-grade VAHL is unlikely to be observed on a scan performed 6 days or longer from vaccination, and is even less likely in older and obese patients.
引用
- Cohen D, Hazut Krauthammer S, Wolf I, et al. A sigh of relief: vaccine-associated hypermetabolic lymphadenopathy following the third COVID-19 vaccine dose is short in duration and uncommonly interferes with the interpretation of [18F]FDG PET-CT studies performed in oncologic patients. Eur J Nucl Med Mol Imaging. 2021. PMID: 34651230. doi:10.1007/s00259-021-05579-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。